A. Geamantan
Faculty of Pharmacy, Victor Babes University of Medicine and Pharmacy, Timisoara, Romania.; Research Center for Pharmaco-Toxicological Evaluations, Faculty of Pharmacy, Victor Babes University of Medicine and Pharmacy, Timisoara, Romania
I. Marcovici
Faculty of Pharmacy, Victor Babes University of Medicine and Pharmacy, Timisoara, Romania.; Research Center for Pharmaco-Toxicological Evaluations, Faculty of Pharmacy, Victor Babes University of Medicine and Pharmacy, Timisoara, Romania
I. Macasoi
Faculty of Pharmacy, Victor Babes University of Medicine and Pharmacy, Timisoara, Romania.; Research Center for Pharmaco-Toxicological Evaluations, Faculty of Pharmacy, Victor Babes University of Medicine and Pharmacy, Timisoara, Romania
C. Dehelean
Faculty of Pharmacy, Victor Babes University of Medicine and Pharmacy, Timisoara, Romania.; Research Center for Pharmaco-Toxicological Evaluations, Faculty of Pharmacy, Victor Babes University of Medicine and Pharmacy, Timisoara, Romania
Abstract
Liver cancer is a public health problem worldwide, hepatocellular carcinoma (HCC) constituting 90% of cases. Although research is in continuous development, the prognosis of this type of cancer remains unfavorable, as selective treatments with low toxicity are necessary. Silibinin is a flavonoid recognized for its hepatoprotective effect, antioxidant and anti-inflammatory properties, and also for its proven effectiveness in cancer treatment when administered indiviadually or in association with conventional therapies.